Back

Notification report


Full notification file


General information

Notification Number
B/FR/13/GT01

Member State to which the notification was sent
France

Date of acknowledgement from the Member State Competent Authority
05/04/2013

Title of the Project
Etude du transfert de gène Serca2a via un vecteur de type AAV 1
(adéno-associated viral 1) pour le traitement de l’insuffisance cardiaque sévère: une étude pilote


Proposed period of release:
01/01/2013 to 31/12/2016

Name of the Institute(s) or Company(ies)
Assistance Publique Hôpitaux de Paris, ;


3. Is the same GMO release planned elsewhere in the Community?
No

Has the same GMO been notified elsewhere by the same notifier?
No

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
Il s’agit du vecteur Adeno-Associated Virus type 1 / Serca2a. Ce vecteur est dérivé du dependovirus de type AAV1/2 et a été modifié pour ne plsu exprimer de génes viraux mais le gène humain SERCA2a (une pompe calcique exprimé celleules musculaires cardiaques normales mais disparaissant dans le coeur pathologique).

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
AAV1Parvoviridae-DependovirusAdeno-Associated Virus type 1N/A

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known